FineMark National Bank & Trust Has $4.68 Million Holdings in Gilead Sciences, Inc. (GILD)

FineMark National Bank & Trust decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.0% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 60,591 shares of the biopharmaceutical company’s stock after selling 1,890 shares during the period. FineMark National Bank & Trust’s holdings in Gilead Sciences were worth $4,678,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Reilly Financial Advisors LLC increased its position in shares of Gilead Sciences by 98.3% during the third quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 704 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $132,000. Brand Asset Management Group Inc. bought a new stake in shares of Gilead Sciences during the second quarter valued at approximately $139,000. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $174,000. Finally, Truvestments Capital LLC bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $210,000. 78.09% of the stock is owned by institutional investors and hedge funds.

NASDAQ:GILD opened at $72.48 on Thursday. The company has a quick ratio of 3.39, a current ratio of 3.47 and a debt-to-equity ratio of 1.36. Gilead Sciences, Inc. has a 12 month low of $64.27 and a 12 month high of $89.54. The company has a market capitalization of $91.20 billion, a price-to-earnings ratio of 10.96, a P/E/G ratio of -2.73 and a beta of 1.01.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. The business had revenue of $5.60 billion during the quarter, compared to the consensus estimate of $5.44 billion. During the same quarter in the previous year, the firm posted $2.27 EPS. On average, sell-side analysts forecast that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 3.15%. The ex-dividend date is Thursday, December 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, November 1st. The shares were sold at an average price of $69.55, for a total value of $3,477,500.00. Following the completion of the sale, the director now owns 3,067,762 shares of the company’s stock, valued at approximately $213,362,847.10. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In the last ninety days, insiders sold 150,000 shares of company stock valued at $11,087,500. 1.30% of the stock is currently owned by insiders.

GILD has been the subject of several analyst reports. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Mizuho reissued a “buy” rating and set a $94.00 price target on shares of Gilead Sciences in a research report on Friday, August 10th. Piper Jaffray Companies set a $85.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, September 12th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research report on Wednesday, July 18th. Thirteen investment analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $87.84.

TRADEMARK VIOLATION NOTICE: This piece of content was published by WKRB News and is owned by of WKRB News. If you are reading this piece of content on another site, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.wkrb13.com/2018/11/08/finemark-national-bank-trust-has-4-68-million-holdings-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Dollar Cost Averaging

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply